The dopamine uptake inhibitor 3α-bis(4′-fluorophenyl)metoxy- tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward

Neuropsychopharmacology

Volumn 34, Issue 12, 2009, Pages 2497-2507

  Velázquez Sánchez, Clara ^a   Ferragud, Antonio ^a   Hernández Rabaza, Vicente ^a   Nácher, Amparo ^a   Merino, Virginia ^a   Cardá, Miguel ^b   Murga, Juan ^b   Canales, Juan J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITAT JAUME I   (Spain)

Author keywords

AHN 1055; BZT derivative; C Fos; Cocaine; Locomotor activity; Place preference

Indexed keywords

3ALPHA [BIS(4' FLUOROPHENYL)METHOXY]TROPANE; AHN 1055; BENZATROPINE; BENZATROPINE DERIVATIVE; COCAINE; DEXAMPHETAMINE; DOPAMINE UPTAKE INHIBITOR; NOMIFENSINE; PROTEIN C FOS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; GENE ACTIVATION; GENE EXPRESSION REGULATION; INSTRUMENTAL CONDITIONING; LOCOMOTION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; REWARD; STEREOTYPY;

ANIMALS; BENZTROPINE; BRAIN; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING, CLASSICAL; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; MALE; MICE; MOTOR ACTIVITY; NOMIFENSINE; PROTO-ONCOGENE PROTEINS C-FOS; REWARD; SPACE PERCEPTION; STEREOTYPED BEHAVIOR;

EID: 70350066489     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.78     Document Type: Article

References (51)

1. Agoston GE, Wu JH, Izenwasser S, George C, Katz J, Kline RH et al (1997a). Novel N-substituted 3 alpha-[bis(40-fluorophenyl)-methoxy]tropane analogues: selective ligands for the dopamine transporter. J Med Chem 40: 4329-4339. (Pubitemid 28042312)
2. Agoston GE, Wu JH, Izenwasser S, George C, Katz J, Kline RH et al (1997b). Novel N-substituted 3 alpha-[bis(40-fluorophenyl)-methoxy]tropane analogues: selective ligands for the dopamine transporter. J Med Chem 40: 4329-4339. (Pubitemid 28042312)
3. Bernard V, Dumartin B, Lamy E, Bloch B (1993). Fos immunor-eactivity after stimulation or inhibition of muscarinic receptors indicates anatomical specificity for cholinergic control of striatal efferent neurons and cortical neurons in the rat. Eur J Neurosci 5: 1218-1225.
4. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K et al (2008). The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11: 780-789.
5. Bonasera SJ, Schenk AK, Luxenberg EJ, Tecott LH (2008). A novel method for automatic quantification of psychostimulant-evoked route-tracing stereotypy: application to Mus musculus. Psycho-pharmacology (Berl) 196: 591-602.
6. Brenhouse HC, Stellar JR (2006). c-Fos and deltaFosB expression are differentially altered in distinct subregions of the nucleus accumbens shell in cocaine-sensitized rats. Neuroscience 137: 773-780.
7. Canales JJ (2005). Intermittent cortical stimulation evokes sensitization to cocaine and enduring changes in matrix and striosome neuron responsiveness. Synapse 57: 56-60.
8. Canales JJ, Gilmour G, Iversen SD (2000). The role of nigral and thalamic output pathways in the expression of oral stereotypies induced by amphetamine injections into the striatum. Brain Res 856: 176-183.
9. Canales JJ, Graybiel AM (2000). A measure of striatal function predicts motor stereotypy. Nat Neurosci 3: 377-383.
10. Canales JJ, Iversen SD (1998). Behavioural topography in the striatum: differential effects of quinpirole and D-amphetamine microinjections. Eur J Pharmacol 362: 111-119.
11. Canales JJ, Iversen SD (2000). Dynamic dopamine receptor interactions in the core and shell of nucleus accumbens differentially coordinate the expression of unconditioned motor behaviors. Synapse 36: 297-306.
12. Carelli RM (2002). The nucleus accumbens and reward: neuro-physiological investigations in behaving animals. Behav Cogn Neurosci Rev 1: 281-296.
13. Carrigan KA, Dykstra LA (2007). Behavioral effects of morphine and cocaine in M1 muscarinic acetylcholine receptor-deficient mice. Psychopharmacology (Berl) 191: 985-993.
14. Chase TD, Carrey N, Brown RE, Wilkinson M (2005). Methyl-phenidate regulates c-fos and fosB expression in multiple regions of the immature rat brain. Brain Res Dev Brain Res 156: 1-12.
15. Chen N, Reith ME (2007). Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. J Neurochem 101: 377-388.
16. Chen N, Zhen J, Reith ME (2004). Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine. J Neurochem 89: 853-864.
17. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O0Brien CP (2005). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205-211.
18. Dar DE, Mayo C, Uhl GR (2005). The interaction of methyl-phenidate and benztropine with the dopamine transporter is different than other substrates and ligands. Biochem Pharmacol 70: 461-469.
19. Desai RI, Kopajtic TA, French D, Newman AH, Katz JL (2005a). Relationship between. J Pharmacol Exp Ther 315: 397-404.
20. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL (2005b). Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25: 1889-1893.
21. Dutta AK, Zhang S, Kolhatkar R, Reith ME (2003). Dopamine transporter as target for drug development of cocaine dependence medications. Eur J Pharmacol 479: 93-106.
22. Grabowski J, Shearer J, Merrill J, Negus SS (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29: 1439-1464.
23. Hernandez-Rabaza V, Hontecillas-Prieto L, Velazquez-Sanchez C, Ferragud A, Perez-Villaba A, Arcusa A et al (2008). The hippo-campal dentate gyrus is essential for generating contextual memories of fear and drug-induced reward. Neurobiol Learn Mem 90: 553-559.
24. Huang X, Zhan CG (2007). How dopamine transporter interacts with dopamine: Insights from molecular modeling and simulation. Biophys J 93: 3627-3639.
25. Ikemoto S (2007). Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 56: 27-78.
26. Indarte M, Madura JD, Surratt CK (2008). Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template. Proteins 70: 1033-1046.
27. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S et al (2008). New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11: 425-438.
28. Katz JL, Agoston GE, Alling KL, Kline RH, Forster MJ, Woolverton WL et al (2001). Dopamine transporter binding without cocainelike behavioral effects: synthesis and evaluation of benztropine analogs alone and in combination with cocaine in rodents. Psychopharmacology (Berl) 154: 362-374.
29. Katz JL, Izenwasser S, Kline RH, Allen AC, Newman AH (1999). Novel 3alpha-diphenylmethoxytropane analogs: selective dopa-mine uptake inhibitors with behavioral effects distinct from those of cocaine. J Pharmacol Exp Ther 288: 302-315.
30. Katz JL, Kopajtic TA, Agoston GE, Newman AH (2004). Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther 309: 650-660.
31. Kosten T, Owens SM (2005). Immunotherapy for the treatment of drug abuse. Pharmacol Ther 108: 76-85.
32. Li SM, Newman AH, Katz JL (2005). Place conditioning and locomotor effects of N-substituted, 40,400-difluorobenztropine analogs in rats. J Pharmacol Exp Ther 313: 1223-1230.
33. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K et al (2008). Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73: 813-823.
34. Moratalla R, Robertson HA, Graybiel AM (1992). Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum. J Neurosci 12: 2609-2622.
35. Raje S, Cao J, Newman AH, Gao H, Eddington ND (2003). Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther 307: 801-808.
36. Raje S, Cornish J, Newman AH, Cao J, Katz JL, Eddington ND (2005). Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral micro-dialysis to evaluate brain dopamine levels and pharmacokinetic/ pharmacodynamic modeling. Pharm Res 22: 603-612.
37. Robertson GS, Jian M (1995). D1 and D2 dopamine receptors differentially increase Fos-like immunoreactivity in accumbal projections to the ventral pallidum and midbrain. Neuroscience 64: 1019-1034.
38. Robinson TE, Kolb B (2004). Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 47(Suppl 1): 33-46.
39. Rodriguez-Alarcon G, Canales JJ, Salvador A (2007). Rewarding effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in dominant and subordinate OF-1 mice in the place preference conditioning paradigm. Prog Neuropsychopharmacol Biol Psychiatry 31: 191-199.
40. Rothman RB (1990). High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci 46: L17-L21.
41. Rothman RB, Baumann MH, Prisinzano TE, Newman AH (2008). Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol 75: 2-16.
42. Sofuoglu M, Kosten TR (2005). Novel approaches to the treatment of cocaine addiction. CNS Drugs 19: 13-25.
43. Tanda G, Ebbs A, Newman AH, Katz JL (2005). Effects of 40-chloro-3 alpha-(diphenylmethoxy)-tropane on mesostriatal, mesocor-tical, and mesolimbic dopamine transmission: comparison with effects of cocaine. J Pharmacol Exp Ther 313: 613-620.
44. Tanda G, Ebbs AL, Kopajtic TA, Elias LM, Campbell BL, Newman AH et al (2007). Effects of muscarinic M1 receptor blockade on cocaine-induced elevations of brain dopamine levels and locomotor behavior in rats. J Pharmacol Exp Ther 321: 334-344.
45. Tanda G, Katz JL (2007). Muscarinic preferential M(1) receptor antagonists enhance the discriminative-stimulus effects of cocaine in rats. Pharmacol Biochem Behav 87: 400-404.
46. Ukairo OT, Bondi CD, Newman AH, Kulkarni SS, Kozikowski AP, Pan S et al (2005). Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther 314: 575-583.
47. Vaughan RA, Agoston GE, Lever JR, Newman AH (1999). Differential binding of tropane-based photoaffinity ligands on the dopamine transporter. J Neurosci 19: 630-636.
48. Volkow ND, Wang GJ, Fischman MW, Foltin R, Fowler JS, Franceschi D et al (2000). Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci 67: 1507-1515.
49. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J et al (1996). Relationship between psychostimulant-induced 'high' and dopamine transporter occupancy. Proc Natl Acad Sci USA 93: 10388-10392.
50. Conover WJ, Iman RL (1981). Rank transformations as a bridge between parametric and non-parametric statistics. Am Stat 35: 124-129.
51. Paxinos G, Franklin KBJ (2001). The Mouse Brain in Stereotaxic Coordinates. Academic Press: New York.